Join Now

Utah Life Sciences News & Events

IONIQ Sciences 2021 Year-End Update

February 10, 2022

Originally published by IONIQ Sciences

Dear IONIQ Sciences Shareholders and Friends,

Greetings from IONIQ Sciences where we continue to follow the science and invest in exceptional team members, advisors and consultants to help us modernize early-stage cancer detection. 

LUNG Cancer – we have submitted our application to the FDA!!

  • We have formally submitted our De Novo application to the FDA seeking marketing clearance in the USA for our ‘breakthrough device‘ in lung cancer. 
  • We appreciate all of the expert input and feedback from our many regulatory consultants and partners. 
  • Our application is now in the hands of the FDA to review and evaluate. We anticipate that it will be months before the FDA engages us with questions and/or additional data requests. 

Expanding our growing LUNG cancer clinical evidence library

Expanding into BREAST Cancer – life-saving potential published in IEEE scientific journal

INTELLECTUAL PROPERTY – portfolio continues to grow

  • We added 2 more patents to our patent portfolio bringing our total to 7 owned patents, 4 licensed and 5 applications. 

RECOGNITION – awareness of our accomplishments continues to grow

  • We added 4 more awards to our trophy case in 2021.
  • We were highlighted another 5 times by patient advocacy groups and news outlets. 
  • We sent out 11 email updates through the year. Click here to see all our news

TEAM – strategically adding exceptional individuals to help us accelerate and expand

Institutional fundraising

  • We continue to thoughtfully evaluate potential life science and strategic partners to join us in modernizing early-stage cancer detection. 

How can you help IONIQ Sciences? Please help us identify people in the SLC-area to scan for approximately 40 minutes. 

  • Healthy subjects across ethnicities.
  • Subjects with lung, breast and/or other cancers.
  • Financial compensation can be provided to subjects.
  • Please contact Mike Garff, IONIQ COO at mag@IONIQsciences.com or 385-501-7002.

Nothing in this email constitutes an offer to buy, or a solicitation of an offer to sell, securities in the United States or any other jurisdiction in which such offer or solicitation would be unlawful. This email is being issued pursuant to and in accordance with Rule 135c under the Securities Act. Please refer to the Company’s latest SEC filings for risk factors, disclosures and forward looking statements. Product is not available for sale in the USA. 

We invite you to follow us on social media where we share updates. Links to our corporate pages can be found at the bottom of this email (@IONIQsciences).